NCT01808833终止不适用
A Pilot Trial of Frailty Assessment in Older Adults (Age 70 >) Requiring Concurrent Chemotherapy Plus Radiation Therapy for Cancer (CTRC# 12-22)
The University of Texas Health Science Center at San Antonio1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2012年2月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Change in frailty assessment due chemotherapy toxicity
研究概览
简要总结
The investigators hypothesize that frailty assessment prior to concurrent chemotherapy and radiation therapy in the elderly will predict treatment-related toxicity and morbidity and that such assessment at serial time points will help improve treatment and outcomes for these patients.
研究设计
- 研究类型
- Observational
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have one of the following histologically or cytologically confirmed cancers: lung cancer, head and neck cancer, gastric cancer, anal cancer, rectal cancer, cervix cancer, or bladder cancer, and must have appropriate indications for the use of standard concurrent chemotherapy plus radiation therapy as defined in the NCCN (National Comprehensive Cancer Network) Guidelines for each of these specific organ-sites.
- •Age >70 years.
- •ECOG (Easter Cooperative Oncology Group) performance status of 0, 1 or
- •Life expectancy Tables showing upper, middle, and lower quartiles of life expectancy for women and men age 70 and older should be used and life expectancy should be estimated to be of sufficient to justify the use of concurrent chemotherapy plus radiation for each organ site and indication.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered to baseline from adverse events due to agents administered more than 4 weeks earlier.
- •Patients who are receiving any investigational agents.
- •Patients with known distant site metastases (M1 disease) or brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients who have a history of one or more other concurrent cancers besides the cancer for which concurrent chemotherapy plus radiation therapy is considered are ineligible only if the other cancer or cancers are being considered for treatment or are actively being treated.
- •Patients carrying a pre-existing diagnosis of HIV/AIDS and are on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- •Patients with any standard contraindication to chemotherapy or radiation therapy are ineligible.
- •Transplant recipient patients on immune-suppressant agents are ineligible due to increased risk of infection.
结局指标
主要结局
Change in frailty assessment due chemotherapy toxicity
时间窗: Subjects will be followed for frailty measures during standard of care chemotherapy treatment, an average of 8 weeks per treatment
Validated frailty measures, and geriatric assessment tools will be used.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With CancerSolid NeoplasmNCT02517034City of Hope Medical Center600
已完成
不适用
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT01026467Wake Forest University Health Sciences45
终止
不适用
Assessment of Frailty in Elderly Patients With Advanced CancersCancerNCT02482285Newcastle-upon-Tyne Hospitals NHS Trust8
已完成
不适用
Education for Prevention and Treatment of FrailtyFrailtyFrail Elderly SyndromeNCT05610605University of Cadiz235
招募中
不适用
Assessing Frailty and Its Impacts on Patients Facing Major GI SurgeryBowel CancerNCT06267378Doncaster And Bassetlaw Hospitals NHS Foundation Trust100